AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

There are many stocks with exceptional dividends to check out. Here are three dividend stocks to double up on right now.

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

AbbVie reported robust fourth-quarter results for 2024, surpassing both top and bottom-line expectations by 2%. The company's immunology drugs, Skyrizi and Rinvoq, exceeded sales forecasts by 5% ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.